Ladenburg Thalmann Maintains Buy Rating and $7.50 PT on Micromet

A report from Ladenburg Thalmann reiterates its Buy rating and $7.50 price target on Micromet (NASDAQ:

). In the report, Ladenburg Thalmann writes, “MITI plans to initiate a US/EU Phase 2b single arm trial with approximately 65 patients by year end. If the results are strong, we believe this trial alone may be the basis for accelerated approval. We expect complete data for all patients could be available by 2H 2013. However, preliminary data could be available as early as 2013 (our estimates) after a significant number of patients complete treatment. If preliminary data is strong, we expect MITI to commence discussions with the FDA regarding accelerated approval”. MITI closed yesterday at $6.11